Page last updated: 2024-11-03

prazosin and Alcohol Drinking

prazosin has been researched along with Alcohol Drinking in 24 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.

Research Excerpts

ExcerptRelevanceReference
"Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking."7.85Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2017)
"Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone."7.81Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2015)
"Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone."7.80Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014)
"This study examined whether prazosin reduces alcohol drinking over the course of prolonged treatment and whether it blocks the initiation of alcohol drinking in rats with a genetic predisposition toward high alcohol drinking, that is alcohol-preferring (P) rats."7.79Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake. ( Federoff, DL; Fischer, SM; Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013)
" Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone."7.79Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. ( Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013)
"The results indicate that the noradrenergic system plays a role in mediating alcohol drinking in rats of the P line and suggest that prazosin--a safe, well-characterized, and well-tolerated drug--may be an effective pharmacotherapeutic agent for the treatment of alcohol use disorders."7.75The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. ( Alexander, LL; Froehlich, JC; Raskind, MA; Rasmussen, DD, 2009)
" CIE/FSS treatment increased anxiety, which was blocked by treatment with the α1-AR inverse agonist prazosin."3.96Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol. ( Blandino, KL; den Hartog, CR; Grampetro, MA; Moorman, DE; Nash, ML; Sjogren, ER; Vazey, EM, 2020)
"Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking."3.85Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2017)
"Prazosin decreases alcohol intake in P rats even in a situation that would be expected to increase alcohol drinking, namely following periods of alcohol deprivation."3.81Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse. ( Fischer, S; Froehlich, JC; Hausauer, B; Rasmussen, DD; Wise, B, 2015)
"Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone."3.81Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2015)
"Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone."3.80Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014)
" Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone."3.79Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. ( Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013)
"Previous studies show that prazosin, an α(1) -adrenergic receptor antagonist, decreases alcohol drinking in animal models of alcohol use and dependence [Rasmussen et al."3.78Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats. ( Czachowski, CL; Froehlich, JC; Rasmussen, DD; Verplaetse, TL, 2012)
"To address this aspect of alcohol use disorder, 102 active-duty soldiers participating in command-mandated Army outpatient alcohol treatment were randomized to also receive the brain-penetrant alpha-1 adrenergic receptor antagonist prazosin or placebo for 13 weeks."3.30A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters. ( Crews, L; Daniels, C; Darnell, J; Goke, K; Hart, K; Hendrickson, R; Holmes, H; Mayer, C; Peskind, ER; Poupore, EL; Raskind, MA; Rasmussen, D; Saxon, A; Simpson, T; Terry, G; Thomas, RG; Williams, T, 2023)
"In Study 1, patients with Alcohol Use Disorder (AUD) (N = 45) with varying AW levels at treatment entry were assessed to examine AW effects on corticostriatal responses to stress, alcohol cue and neutral visual images with functional magnetic resonance imaging (fMRI)."3.11Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder. ( Angarita, G; Fogelman, N; Hermes, G; Seo, D; Sinha, R; Wemm, S, 2022)
"Veterans with comorbid alcohol dependence and PTSD (n = 96) were randomized to prazosin (16 mg) or placebo in a 12-week outpatient, double-blind clinical trial."2.90Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. ( Gueorguieva, R; McKee, SA; Petrakis, IL; Ralevski, E; Roberts, W; Verplaetse, TL, 2019)
" Medication was titrated to a target dosing schedule of 4 mg in the morning, 4 mg in the afternoon, and 8 mg at bedtime by the end of week 2."2.87Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. ( Lyons, R; Malte, CA; Millard, SP; Raskind, M; Saxon, AJ; Simpson, TL; Stappenbeck, C; Tell, D, 2018)
"Within the PTSD group, combat exposure was associated with increased drinking independent of the severity of PTSD symptoms."2.79Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. ( Arias, AJ; Fuehrlein, B; Jane, JS; O'Brien, E; Petrakis, IL; Ralevski, E, 2014)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.17)18.7374
1990's1 (4.17)18.2507
2000's1 (4.17)29.6817
2010's16 (66.67)24.3611
2020's5 (20.83)2.80

Authors

AuthorsStudies
Sinha, R3
Andrade, C1
Fogelman, N1
Wemm, S1
Angarita, G1
Seo, D1
Hermes, G1
Raskind, MA2
Williams, T1
Holmes, H1
Hart, K1
Crews, L1
Poupore, EL1
Thomas, RG1
Darnell, J1
Daniels, C1
Goke, K1
Hendrickson, R1
Terry, G1
Mayer, C1
Simpson, T1
Saxon, A1
Rasmussen, D1
Peskind, ER1
den Hartog, CR1
Blandino, KL1
Nash, ML1
Sjogren, ER1
Grampetro, MA1
Moorman, DE1
Vazey, EM1
Simpson, TL2
Saxon, AJ2
Stappenbeck, C1
Malte, CA1
Lyons, R1
Tell, D1
Millard, SP1
Raskind, M2
Verplaetse, TL2
Ralevski, E2
Roberts, W1
Gueorguieva, R1
McKee, SA1
Petrakis, IL2
Kleinman, RA1
Ostacher, MJ1
Froehlich, JC8
Hausauer, BJ2
Federoff, DL1
Fischer, SM1
Rasmussen, DD8
Fuehrlein, B1
O'Brien, E1
Jane, JS1
Arias, AJ1
Beckwith, LE1
Kincaid, CL3
Skelly, MJ2
Weiner, JL2
Chappell, AE1
Carter, E1
Hausauer, B1
Fischer, S1
Wise, B1
Funk, D1
Coen, K1
Tamadon, S1
Li, Z1
Loughlin, A1
Lê, AD1
Alexander, LL1
Czachowski, CL1
Miyamae, M1
Camacho, SA1
Zhou, HZ1
Diamond, I1
Figueredo, VM1
Aalto, J1
Kiianmaa, K1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)[NCT02109562]Phase 3354 participants (Actual)Interventional2014-04-30Completed
Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence[NCT00762710]Phase 292 participants (Actual)Interventional2008-01-31Completed
Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders[NCT03894345]Phase 120 participants (Anticipated)Interventional2019-05-24Suspended (stopped due to COVID-19)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in Clinical Global Impression - Severity Scale (CGI-S)

"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Negative change from baseline scores indicate improvement in the severity of illness.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation

Interventionunits on a scale (Least Squares Mean)
RBP-7000 90 mg-0.868
RBP-7000 120 mg-0.914
Placebo-0.518

Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score

"The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor judgement, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation

Interventionunits on a scale (Least Squares Mean)
RBP-7000 90 mg-15.367
RBP-7000 120 mg-16.456
Placebo-9.219

Summary of Participants With Treatment-Emergent Adverse Events (TEAE)

"An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug.~A serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories." (NCT02109562)
Timeframe: Day 1 to Week 8

,,
InterventionParticipants (Count of Participants)
No TEAEs1 or more TEAEsRelated TEAESerious TEAESerious, related TEAETEAE causing discontinuationDeath
Placebo3781501030
RBP-7000 120 mg2691651020
RBP-7000 90 mg3481580000

Alcohol Consumption

At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period (NCT00762710)
Timeframe: 12 weeks

,
Interventionpercentage of days heavy drinking (Mean)
Baseline % Days Heavy DrinkingFinal medication week % Days Heavy Drinking
Placebo66.522.6
Prazosin71.811.4

Trials

5 trials available for prazosin and Alcohol Drinking

ArticleYear
Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder.
    Addiction biology, 2022, Volume: 27, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Craving; Humans; Prazosin; Substance Withdrawal Syndrome

2022
A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters.
    Alcohol, clinical & experimental research, 2023, Volume: 47, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Ethanol; Humans; Military Personnel; Prazosin; Su

2023
Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.
    The American journal of psychiatry, 2018, 12-01, Volume: 175, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Adm

2018
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.
    Alcoholism, clinical and experimental research, 2019, Volume: 43, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholi

2019
Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder.
    Addictive behaviors, 2014, Volume: 39, Issue:2

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Alcohol Drinking; Alcoholism; Comorbidity; Co

2014

Other Studies

19 other studies available for prazosin and Alcohol Drinking

ArticleYear
Prazosin for Alcohol Use Disorder: A Clarification.
    The Journal of clinical psychiatry, 2021, 09-21, Volume: 82, Issue:6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Humans; Prazosin

2021
Prazosin for Alcohol Use Disorder: Reply to Sinha.
    The Journal of clinical psychiatry, 2021, 09-21, Volume: 82, Issue:6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Humans; Prazosin

2021
Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol.
    Psychopharmacology, 2020, Volume: 237, Issue:10

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Anxiety; Ethanol; Female; Locus

2020
Prazosin for the Treatment of Alcohol Use Disorders.
    The American journal of psychiatry, 2018, 12-01, Volume: 175, Issue:12

    Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin

2018
Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher.
    The American journal of psychiatry, 2019, 02-01, Volume: 176, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin

2019
Prazosin and Alcohol Use Disorder.
    The American journal of psychiatry, 2019, 02-01, Volume: 176, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin

2019
Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake.
    Alcoholism, clinical and experimental research, 2013, Volume: 37, Issue:9

    Topics: Alcohol Drinking; Animals; Breeding; Dose-Response Relationship, Drug; Ethanol; Male; Prazosin; Rand

2013
Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
    Alcoholism, clinical and experimental research, 2013, Volume: 37, Issue:10

    Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals

2013
Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.
    Alcoholism, clinical and experimental research, 2014, Volume: 38, Issue:6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism;

2014
Chronic treatment with prazosin or duloxetine lessens concurrent anxiety-like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety-related alcohol use.
    Brain and behavior, 2014, Volume: 4, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Alcohol Drinking; Animals; An

2014
Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.
    Neuropharmacology, 2015, Volume: 97

    Topics: Aging; Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Central Nervous System Depressants;

2015
Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.
    Alcoholism, clinical and experimental research, 2015, Volume: 39, Issue:8

    Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Disease Models, Animal; Male; Prazosin; R

2015
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
    Alcoholism, clinical and experimental research, 2015, Volume: 39, Issue:9

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combin

2015
Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats.
    Psychopharmacology, 2016, Volume: 233, Issue:11

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alcohol Drinking; Animals; Br

2016
Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2017, Volume: 52, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Anxiety; Dose-Response Relations

2017
The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats.
    Alcoholism, clinical and experimental research, 2009, Volume: 33, Issue:2

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alcohol Drinking; Animals; Da

2009
Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats.
    Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:5

    Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Appetitive Behavior; Central Ner

2012
Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pigs and rats.
    The American journal of physiology, 1998, Volume: 275, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Animals; Blood Pressure; Coronary Circulation; Creatine Kinase; Diasto

1998
Role of brain monoaminergic systems in the increased ethanol drinking caused by REM-sleep deprivation.
    Alcohol and alcoholism (Oxford, Oxfordshire). Supplement, 1987, Volume: 1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Animals; Brain Chemistry; Catecholamines; Citalopr

1987